Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
AML1-ETO meets JAK2: clinical evidence for the two hit model of leukemogenesis from a myeloproliferative syndrome progressing to acute myeloid leukemia.
Schneider F, Bohlander SK, Schneider S, Papadaki C, Kakadyia P, Dufour A, Vempati S, Unterhalt M, Feuring-Buske M, Buske C, Braess J, Wandt H, Hiddemann W, Spiekermann K. Schneider F, et al. Among authors: vempati s. Leukemia. 2007 Oct;21(10):2199-201. doi: 10.1038/sj.leu.2404830. Epub 2007 Jul 12. Leukemia. 2007. PMID: 17625612 No abstract available.
CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes.
Reindl C, Quentmeier H, Petropoulos K, Greif PA, Benthaus T, Argiropoulos B, Mellert G, Vempati S, Duyster J, Buske C, Bohlander SK, Humphries KR, Hiddemann W, Spiekermann K. Reindl C, et al. Among authors: vempati s. Clin Cancer Res. 2009 Apr 1;15(7):2238-47. doi: 10.1158/1078-0432.CCR-08-1325. Epub 2009 Mar 10. Clin Cancer Res. 2009. PMID: 19276253
Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL.
Stubbs MC, Kim W, Bariteau M, Davis T, Vempati S, Minehart J, Witkin M, Qi J, Krivtsov AV, Bradner JE, Kung AL, Armstrong SA. Stubbs MC, et al. Among authors: vempati s. Clin Cancer Res. 2015 May 15;21(10):2348-58. doi: 10.1158/1078-0432.CCR-14-1290. Epub 2015 Feb 16. Clin Cancer Res. 2015. PMID: 25688158 Free PMC article.
H3K79 methylation profiles define murine and human MLL-AF4 leukemias.
Krivtsov AV, Feng Z, Lemieux ME, Faber J, Vempati S, Sinha AU, Xia X, Jesneck J, Bracken AP, Silverman LB, Kutok JL, Kung AL, Armstrong SA. Krivtsov AV, et al. Among authors: vempati s. Cancer Cell. 2008 Nov 4;14(5):355-68. doi: 10.1016/j.ccr.2008.10.001. Cancer Cell. 2008. PMID: 18977325 Free PMC article.
MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L.
Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV, Feng Z, Punt N, Daigle A, Bullinger L, Pollock RM, Richon VM, Kung AL, Armstrong SA. Bernt KM, et al. Among authors: vempati s. Cancer Cell. 2011 Jul 12;20(1):66-78. doi: 10.1016/j.ccr.2011.06.010. Cancer Cell. 2011. PMID: 21741597 Free PMC article.
Right On Time: Ultrafast Charge Separation Before Hybrid Exciton Formation.
Gierster L, Turkina O, Deinert JC, Vempati S, Baeta E, Garmshausen Y, Hecht S, Draxl C, Stähler J. Gierster L, et al. Among authors: vempati s. Adv Sci (Weinh). 2024 Aug;11(31):e2403765. doi: 10.1002/advs.202403765. Epub 2024 Jun 14. Adv Sci (Weinh). 2024. PMID: 38874072 Free PMC article.
40 results